Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, is an effective treatment option for rheumatoid arthritis (RA), but its use has been associated with an increased risk of digestive events. This systematic review aimed to investigate the risk of digestive events in RA patients treated with UPA.

Methods

Systematic searches of electronic databases (PubMed, Cochrane Library, and EMBASE) from inception to September 2022 were conducted to locate randomized controlled trials (RCTs) that compared UPA with control treatment and reported digestive events in RA patients. We pooled data using the random-effects model and meta-analysis was conducted by Stata software.

Results

Ten RCTs met the inclusion criteria and were analyzed, with a total of 6103 patients.

SUBMITTER: Liu-Yan N 

PROVIDER: S-EPMC10361017 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature